enGene to Participate in Upcoming Investor Conferences

On August 27, 2025 enGene Holdings Inc. (Nasdaq: ENGN or "enGene"), a clinical-stage, non-viral gene therapy company, reported that management will participate in the following investor conferences in September (Press release, enGene, AUG 27, 2025, View Source [SID1234655538]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

2025 Wells Fargo Healthcare Conference
Date: Wednesday, September 3, 2025
Time: 8:45 a.m. ET

H.C. Wainwright 27th Annual Global Investment Conference
Date: Monday, September 8, 2025
Time: 1:30 p.m. ET

Morgan Stanley 23rd Annual Global Healthcare Conference
Date: Wednesday, September 10, 2025
Time: 1:50 p.m. ET

A live webcast of these events can be accessed under the "Investors" section of the enGene website at www.engene.com and will be archived there for 90 days.

CEL-SCI Announces Pricing of $10 Million Public Offering

On August 27, 2025 CEL-SCI Corporation ("CEL-SCI" or the "Company") (NYSE American: CVM), a clinical stage cancer immunotherapy company, reported the pricing of a best-efforts public offering of 1,111,200 shares of its common stock (Press release, Cel-Sci, AUG 27, 2025, View Source [SID1234655537]). Each share of common stock is being sold at a public offering price of $9.00 per share. Total gross proceeds from the offering, before deducting the placement agent’s fees and other offering expenses, are expected to be approximately $10 million. The offering is expected to close on August 29, 2025, subject to satisfaction of customary closing conditions.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Company intends to use the net proceeds from the offering to fund the continued development of Multikine, general corporate purposes, and working capital.

ThinkEquity is acting as the sole placement agent for the offering.

The securities will be offered and sold pursuant to a shelf registration statement on Form S-3 (File No. 333-288515), including a base prospectus, filed with the U.S. Securities and Exchange Commission (the "SEC") on July 3, 2025, and declared effective on August 12, 2025. The offering will be made only by means of a written prospectus. A final prospectus supplement and accompanying prospectus describing the terms of the offering will be filed with the SEC on its website at www.sec.gov. Copies of the prospectus supplement and the accompanying prospectus relating to the offering may also be obtained, when available, from the offices of ThinkEquity, 17 State Street, 41st Floor, New York, New York 10004.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Personalis to Participate in Upcoming Investor Conferences

On August 27, 2025 Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, reported that its management team will be attending the following conferences (Press release, Personalis, AUG 27, 2025, View Source [SID1234655536]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Morgan Stanley 23rd Annual Global Healthcare Conference on Wednesday, September 10, 2025, at the Sheraton New York Times Square Hotel in New York, NY
Lake Street 9th Annual Best Ideas Growth Conference on Thursday, September 11, 2025, at the Yale Club in New York, NY

Nuvation Bio to Participate in Upcoming Investor Conferences

On August 27, 2025 Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, reported that David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio, and Philippe Sauvage, Chief Financial Officer of Nuvation Bio, will participate in three upcoming investor conferences, including fireside chats at two conferences (Press release, Nuvation Bio, AUG 27, 2025, View Source [SID1234655535]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Cantor Global Healthcare Conference 2025 on Thursday, September 4, 2025, at 2:10 p.m. ET in New York, NY
H.C. Wainwright 27th Annual Global Investment Conference on Tuesday, September 9, 2025, at 11:30 a.m. ET in New York, NY
The management team will participate in one-on-one meetings at the Citi 2025 BioPharma Back to School Conference on Wednesday, September 3, 2025, in Boston, MA.

Live webcasts of each fireside chat will be available on the Investor Relations section of the Nuvation Bio website. An archived recording will be available for 90 days following each event.

Oncoinvent ASA half-yearly report: Strong focus on financial discipline and advancing Phase 2 program in ovarian cancer

On August 27, 2025 Oncoinvent reported continued progress in the ongoing Phase 2 trial in ovarian cancer with a strong focus on advancing the program and maximizing recruitment (Press release, Oncoinvent, AUG 27, 2025, View Source [SID1234655534]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Highlights for the first half of 2025:

Radspherin

Positive final data from Phase1/2a trial in colorectal cancer patients
Positive interim 18-months data from Phase1 trial in ovarian cancer patients
Positive read-out of safety lead-in cohort and opening of randomized part of Phase 2 trial in ovarian cancer patients
Regulatory approvals for additional sites for the randomized Phase 2 trial in ovarian cancer, with expected onboarding before end of 2025
Corporate

Operating expenses reduced by 28% versus last year
Merger with BerGenBio
Fully guaranteed rights issue of NOKm 130
CEO Øystein Soug and CFO Tore Kvam will present the results for the first half of 2025 at a webcast available at https://channel.royalcast.com/landingpage/hegnarmedia/20250827_3/, Wednesday 27 August at 08:00 CEST. The presentation and Q&A will be held in English. A recording of the webcast will be made available on our website shortly after the presentation.